TY - JOUR
T1 - Profiling humoral responses to COVID-19 immunization in Kawasaki disease using SARS-CoV-2 variant protein microarrays
AU - Keskin, Batuhan Birol
AU - Liu, Shih Feng
AU - Du, Pin Xian
AU - Tsai, Pei Shan
AU - Ho, Tzong Shiann
AU - Su, Wen Yu
AU - Lin, Pei Chun
AU - Shih, Hsi Chang
AU - Weng, Ken Pen
AU - Yang, Kuender D.
AU - Huang, Ying Hsien
AU - Kuo, Kuang Che
AU - Syu, Guan Da
AU - Kuo, Ho Chang
N1 - Publisher Copyright:
© 2023 The Royal Society of Chemistry.
PY - 2023/8/8
Y1 - 2023/8/8
N2 - Kawasaki disease (KD) is a form of acute systemic vasculitis syndrome that predominantly occurs in children under the age of 5 years. Its etiology has been postulated due to not only genetic factors but also the presence of foreign antigens or infectious agents. To evaluate possible associations between Kawasaki disease (KD) and COVID-19, we investigated humoral responses of KD patients against S-protein variants with SARS-CoV-2 variant protein microarrays. In this study, plasma from a cohort of KD (N = 90) and non-KD control (non-KD) (N = 69) subjects in categories of unvaccinated-uninfected (pre-pandemic), SARS-CoV-2 infected (10-100 days after infection), and 1-dose, 2-dose, and 3-dose BNT162b2 vaccinated (10-100 days after vaccination) was collected. The principal outcomes were non-KD-KD differences for each category in terms of anti-human/anti-His for binding antibodies and neutralizing percentage for surrogate neutralizing antibodies. Binding antibodies against spikes were lower in the KD subjects with 1-dose of BNT162b2, and mean differences were significant for the P.1 S-protein (non-KD-KD, 3401; 95% CI, 289.0 to 6512; P = 0.0252), B.1.617.2 S-protein (non-KD-KD, 4652; 95% CI, 215.8 to 9087; P = 0.0351) and B.1.617.3 S-protein (non-KD-KD, 4874; 95% CI, 31.41 to 9716; P = 0.0477). Neutralizing antibodies against spikes were higher in the KD subjects with 1-dose of BNT162b2, and mean percentage differences were significant for the 1-dose BNT162b2 B.1.617.3 S-protein (non-KD-KD, −22.89%; 95% CI, −45.08 to −0.6965; P = 0.0399), B.1.1.529 S-protein (non-KD-KD, −25.96%; 95% CI, −50.53 to −1.376; P = 0.0333), BA.2.12.1 S-protein (non-KD-KD, −27.83%; 95% CI, −52.55 to −3.115; P = 0.0195), BA.4 S-protein (non-KD-KD, −28.47%; 95% CI, −53.59 to −3.342; P = 0.0184), and BA.5 S-protein (non-KD-KD, −30.42%; 95% CI, −54.98 to −5.869; P = 0.0077). In conclusion, we have found that KD patients have a comparable immunization response to healthy individuals to SARS-CoV-2 infection and COVID-19 immunization.
AB - Kawasaki disease (KD) is a form of acute systemic vasculitis syndrome that predominantly occurs in children under the age of 5 years. Its etiology has been postulated due to not only genetic factors but also the presence of foreign antigens or infectious agents. To evaluate possible associations between Kawasaki disease (KD) and COVID-19, we investigated humoral responses of KD patients against S-protein variants with SARS-CoV-2 variant protein microarrays. In this study, plasma from a cohort of KD (N = 90) and non-KD control (non-KD) (N = 69) subjects in categories of unvaccinated-uninfected (pre-pandemic), SARS-CoV-2 infected (10-100 days after infection), and 1-dose, 2-dose, and 3-dose BNT162b2 vaccinated (10-100 days after vaccination) was collected. The principal outcomes were non-KD-KD differences for each category in terms of anti-human/anti-His for binding antibodies and neutralizing percentage for surrogate neutralizing antibodies. Binding antibodies against spikes were lower in the KD subjects with 1-dose of BNT162b2, and mean differences were significant for the P.1 S-protein (non-KD-KD, 3401; 95% CI, 289.0 to 6512; P = 0.0252), B.1.617.2 S-protein (non-KD-KD, 4652; 95% CI, 215.8 to 9087; P = 0.0351) and B.1.617.3 S-protein (non-KD-KD, 4874; 95% CI, 31.41 to 9716; P = 0.0477). Neutralizing antibodies against spikes were higher in the KD subjects with 1-dose of BNT162b2, and mean percentage differences were significant for the 1-dose BNT162b2 B.1.617.3 S-protein (non-KD-KD, −22.89%; 95% CI, −45.08 to −0.6965; P = 0.0399), B.1.1.529 S-protein (non-KD-KD, −25.96%; 95% CI, −50.53 to −1.376; P = 0.0333), BA.2.12.1 S-protein (non-KD-KD, −27.83%; 95% CI, −52.55 to −3.115; P = 0.0195), BA.4 S-protein (non-KD-KD, −28.47%; 95% CI, −53.59 to −3.342; P = 0.0184), and BA.5 S-protein (non-KD-KD, −30.42%; 95% CI, −54.98 to −5.869; P = 0.0077). In conclusion, we have found that KD patients have a comparable immunization response to healthy individuals to SARS-CoV-2 infection and COVID-19 immunization.
UR - http://www.scopus.com/inward/record.url?scp=85170279956&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85170279956&partnerID=8YFLogxK
U2 - 10.1039/d3an00802a
DO - 10.1039/d3an00802a
M3 - Article
C2 - 37610260
AN - SCOPUS:85170279956
SN - 0003-2654
VL - 148
SP - 4698
EP - 4709
JO - Analyst
JF - Analyst
IS - 19
ER -